Realized +15.91% in 36 days from the tracked date (reference price $47.45). Call closed and archived — this report is a historical document, no longer maintained.
SKWD is a high-quality specialty P&C underwriter: a sub-90 combined ratio (89.5% in Q1-26), a 20.3% operating return on equity and book value compounding 31% year-over-year. Yet the stock trades at just ~1.65x book and ~10x forward earnings, near its 52-week low and roughly 30% below the analyst consensus — a valuation that prices in cyclicality, the Apollo (Lloyd's) integration and a 2025 data breach more harshly than the fundamentals warrant. The thesis is a re-rating, not a turnaround; the main risks are insurance-cycle softening and reserve adequacy, both manageable. Base-case fair value ~$55, ~+21% above the current price.
Methodology: P/B and P/E blended at 55/45, then risk-discounted. The probability-weighted expected value across the three scenarios is ~$56, consistent with the $55 base case and tilted modestly to the upside given a downside that is well-anchored by tangible book value. Key swing factors: the insurance pricing cycle, catastrophe load and reserve development. ⚠️ Not investment advice.
| Component | Assumption | USD/share |
|---|---|---|
| P/B method (reference) | YE-2026E BVPS ~$31.0 × 2.05x justified P/B (20%+ ROE, discounted vs KNSL/RLI) | 63.60 |
| P/E method (reference) | FY26E EPS $4.60 (guidance midpoint) × 12.0x specialty-insurer peer P/E | 55.20 |
| Blended fair value | 55% × 63.60 + 45% × 55.20 (P/B-weighted blend) | 59.80 |
| Apollo integration & Lloyd's discount | −5%: first full year of integration, FX and syndicate-result volatility | −3.00 |
| Data-breach & soft-market overhang | −3%: residual 2025 breach litigation risk + softening E&S pricing | −1.80 |
| FV base case | 59.80 − 3.00 − 1.80 = blended, risk-adjusted fair value | ≈ $55.00 |
Short interest is estimated and low-to-moderate — the bar is scaled to a 30% "very high" ceiling. This is not a squeeze story: the bull case rests on a fundamental re-rating, not on positioning. Insider activity tilts constructive — a director added 7,000 shares over the past year (none sold), including a May-2026 purchase near $47.
| Item | FY2023 | FY2024 | FY2025 | Guidance 2026 |
|---|---|---|---|---|
| Gross written premiums ($M) | ~1,270 | ~1,742 | 2,166 | 2,650–2,800 |
| Net income ($M) | ~107 | ~133 | 170.0 | 207–216 |
| Diluted EPS ($) | ~2.65 | ~3.20 | 4.07 | 4.50–4.70 |
| Combined ratio (%) | ~91.5 | ~91.0 | ~91.0 | 90.5–91.5 |
| Book value / share ($) | ~16.5 | ~21.0 | ~25.0 | ~31.0E |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Gross written premiums ($M) | 610E | 555E | 545E | 456E | 668 |
| Combined ratio (%) | 91E | 91E | 92E | 90E | 89.5 |
| Net income ($M) | 40E | 43E | 42E | 45E | 50 |
| Book value / share ($) | 21.0E | 22.5E | 23.5E | 25.0E | 27.50 |
Business model — Skyward Specialty Insurance Group
US specialty & E&S ~$2.2–2.3B GWP FY26E (~82% of group) 🟢 core engine Eight specialty divisions of niche P&C risk. Drives the sub-90 combined ratio; growth from disciplined rate and new-team additions rather than cycle-chasing. Apollo (Lloyd's platform) ~$0.4–0.5B GWP FY26E (~16% of group) 🟡 integrating Acquired Jan-2026; a Lloyd's managing agent adding international specialty lines. Contributed ~$80M revenue and ~$22M net income in Q1-26. Integration is the key 2026 execution item. Fee-generating / captives ~$300M fee premium, capital-light 🟢 fastest-growing Managed-premium and captive programs that earn fee income with limited balance-sheet risk. Fee premiums grew 49% YoY — a higher-return, lower-volatility revenue stream.
Legal, regulatory and risk analysis
SWOT analysis
- +Sub-90 combined ratio — genuine underwriting profitability
- +20.3% operating ROE, book value compounding 31% YoY
- +Niche, less-commoditised specialty focus reduces price competition
- +Fast-growing, capital-light fee-generating premium book (+49% YoY)
- +Experienced management with a proven turnaround/IPO track record
- −Short public track record (IPO 2023) — limited cycle history
- −Smaller scale than KNSL, RLI, WRB — less diversification
- −Apollo added ~$371M of debt and modest share dilution
- −2025 data breach is a residual reputational overhang
- →Re-rating toward peer P/B multiples as the record lengthens
- →Apollo opens international and new Lloyd's specialty lines
- →Continued growth of high-return fee/managed-premium business
- →Rising net investment income ($115–120M guided) as float grows
- !Softening E&S/specialty pricing cycle compressing margins
- !Adverse reserve development on long-tail casualty lines
- !A severe catastrophe year lifting the combined ratio
- !Sector-wide de-rating of specialty insurers regardless of results
Summary by assessment area
- 20%+ ROE, sub-90 combined ratio, profitable and growing
- Book value compounding 31% YoY with no dividend leakage
- Apollo debt modest and well within insurer norms
- Softening E&S pricing and cat load are the key swing factors
- Reserve adequacy on long-tail lines needs monitoring
- Niche focus and fee mix dampen, not remove, cyclicality
- Base-case FV ~$55 vs price ~$45.50 — ~21% upside
- 1.65x book is a clear discount to similar-ROE peers
- Downside anchored by growing tangible book value
Sources: Skyward Specialty 8-K and 10-Q filings FY2025–FY2026 (Q1-2026 results, FY2025 results, Apollo approval / 2026 guidance), Skyward Specialty Q1-2026 earnings release and call transcript, StockTitan, ChartMill, SEC EDGAR filings, MarketBeat / Benzinga / TipRanks / public.com analyst consensus, StockAnalysis.com, Simply Wall St, Form 4 insider-trading filings, data-breach litigation investigation notices. Market data (2026-05-24, verified across ≥2 recent sources): SKWD ~$45.50 (close ~May 22, 2026; quoted $44–47 across recent sessions), market cap ~$2.0B, 52W range $40.60–$65.05, ~44.5M shares outstanding. Short interest ~5–6% (estimated). Book value per share $27.50 (Q1-2026). Several FY2023–FY2024 and quarterly-split figures are estimates and are labelled as such. This document is for informational purposes only and does not constitute financial or investment advice.